How Galapagos is taking its lead compound filgotinib for rheumatoid arthritis and Crohn's disease into phase III trials




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How Galapagos is taking its lead compound filgotinib for rheumatoid arthritis and Crohn's disease into phase III trials
Released on: October 15, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Galapagos is a well-funded European mid-sized Biotech listed on the US NASDAQ, with a JAKs discovery platform with which it has various collaborations.
  • Summary
  • Transcript
  • Participants
  • Company
Galapagos is a well-funded European mid-sized Biotech listed on the US NASDAQ, with a JAKs discovery platform with which it has various collaborations. Nathalie ter Wengel, Director of Business Development at Galapagos, talks with Fintan Walton, CEO of PharmaVentures, about their latest news. This includes news on their lead program filgotinib, for rheumatoid arthritis (RA) and potentially other inflammatory diseases, which they are soon taking into Phase III trials. The status of their other programmes is also discussed, including another partnered programme with Abbvie in the area of Cystic Fibrosis.
Galapagos is a well-funded European mid-sized Biotech listed on the US NASDAQ, with a JAKs discovery platform with which it has various collaborations. Nathalie ter Wengel, Director of Business Development at Galapagos, talks with Fintan Walton, CEO of PharmaVentures, about their latest news. This includes news on their lead program filgotinib, for rheumatoid arthritis (RA) and potentially other inflammatory diseases, which they are soon taking into Phase III trials. The status of their other programmes is also discussed, including another partnered programme with Abbvie in the area of Cystic Fibrosis.
Nathalie ter Wengel
Galapagos
Galapagos develops drugs to treat bone and joint ailments, amongst other diseases. Its research and development team has partnered with many global pharma companies, including GSK, Merck & Co. and Eli Lilly